- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
X4 Pharmaceuticals Inc (XFOR)
The X4 Pharmaceuticals share price today is 3.250, view NASDAQ XFOR stock exchange data. Track the latest X4 Pharmaceuticals share price with real-time updates on XFOR stock performance including market cap, day range, 52-week range and dividend yield. Access XFOR charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.140
3.300
52 wk Range
2.430
4.830
XFOR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.1403.300
52 wk Range
2.4304.830
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
XFOR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
11.600
Upside
+256.92%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
X4 Pharma chairman Craig R. sells $210,829 in shares- Investing.com
Form 144 X4 Pharmaceuticals For: 1 October- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.600
(+256.92% Upside)
X4 Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- X4 Pharmaceuticals reports Q1 2025 EPS of $0.04, beating -$0.12 forecast; revenue reaches $28.81M vs $12.03M expected
- Strategic restructuring aims to reduce annual spending by $30-35M; company maintains $90M cash, sufficient until H1 2026
- FORWARD trial enrollment to complete by Q3/Q4 2025; top-line data expected H2 2026; EMA approval for WHIM indication targeted Q1 2026
- Stock declines 1.42% in premarket despite earnings beat; company faces high R&D/SG&A expenses and clinical trial enrollment challenges
- CEO expresses confidence in meeting milestones; CCO highlights high compliance rates for daily oral medication in chronic neutropenia market
Last Updated: 01-05-2025, 06:56 pm
Read Full TranscriptEarnings
Latest Release
06-08-2026
EPS / Forecast
-0.13 / -0.19
Revenue / Forecast
8.81M / 2.28M
Compare XFOR to Peers and Sector
Metrics to compare | XFOR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXFORPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.6x | −0.9x | −0.3x | |
PEG Ratio | −0.04 | −0.02 | 0.00 | |
Price/Book | 2.1x | 2.4x | 2.6x | |
Price / LTM Sales | 20.3x | 6.8x | 2.8x | |
Upside (Analyst Target) | 256.9% | 306.8% | 64.7% | |
Fair Value Upside | Unlock | 19.9% | 9.6% | Unlock |
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the X4 Pharmaceuticals (XFOR) Share Price Today?
The X4 Pharmaceuticals share price today is 3.250.
What is the current X4 Pharmaceuticals (XFOR) share price and day range?
As of 27-10-2026, the X4 Pharmaceuticals share price is 3.250, with a previous close of 3.250. The share price has ranged from 3.140 to 3.300 today, while the 52-week range spans from 2.430 to 4.830.
What Is the X4 Pharmaceuticals Market Cap?
As of today, X4 Pharmaceuticals market cap is 322.230M.
What Is the X4 Pharmaceuticals (XFOR) Share Price Target?
The average 12-month share price target for X4 Pharmaceuticals is 11.600, with a high estimate of 13 and a low estimate of 10. 5 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +256.92% Upside potential.
What Is X4 Pharmaceuticals's Earnings Per Share (TTM)?
The X4 Pharmaceuticals EPS (TTM) is -0.88.
When Is the Next X4 Pharmaceuticals Earnings Date?
X4 Pharmaceuticals will release its next earnings report on 29-10-2026.
From a Technical Analysis Perspective, Is XFOR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
What Stock Exchange Does X4 Pharmaceuticals Trade On?
X4 Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for X4 Pharmaceuticals?
The stock symbol for X4 Pharmaceuticals is "XFOR."
How Many Times Has X4 Pharmaceuticals Stock Split?
X4 Pharmaceuticals has split 2 times.
How Many Employees Does X4 Pharmaceuticals Have?
X4 Pharmaceuticals has 45 employees.
What Is the XFOR Premarket Price?
XFOR's last pre-market stock price is 3.300. The pre-market share volume is 60.000, and the stock has changed by 0.050, or 1.540%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.